Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular fingerprint of breast cancer drug resistance can predict response to treatment

25.09.2007
A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14) today (Monday 24 September).

Dr Iain Brown, from the University of Aberdeen, Aberdeen, Scotland, told the conference that he and his colleague, Dr Andrew Schofield, had identified two genes that could identify which cells would be resistant and which would respond to docetaxel.

Docetaxel is one of the most effective chemotherapy treatments in advanced breast cancer. It works by binding to cell components called microtubules, and stabilising them so that they do not disassemble. They then accumulate within the cell and bring about apoptosis, or cell death. “However, up to half of all patients treated with this drug will develop resistance, and hence the treatment will fail,” said Dr Brown.

The scientists decided to look for a specific genetic make-up in patients where docetaxel treatment had failed, in the hope that this might explain why they became resistant to the drug. They used micro-array analysis, a technique that allowed them to look at every known gene in our cells at once, to identify genes that were significantly associated with such resistance.

“By going back to the laboratory, using breast cancer cell lines, we can eliminate much of the variation in gene expression found in different patients, and thus remove a lot of ‘background noise’,” said Dr Brown. “We developed a unique model of docetaxel resistance in breast cancer from two different cell lines made resistant to the drug by exposing them to increasing concentrations of the drug. This model has also allowed us to test cells which are resistant to low levels of the drug and cells which are resistant to high levels.”

Drs Brown and Schofield now intend to carry the research further, by applying their findings to patient samples to see whether the gene set they have discovered has the ability to predict response to docetaxel in a patient who has undergone treatment with the drug. “At the moment we have only tested this in cell lines,” said Dr Brown, “but we do believe these results may be translated into the clinical setting and benefit the patient. In essence, we have taken a clinical problem back to the laboratory, and now we intend to take this back to the bedside.”

The scientists will start collecting tissue samples from patients within the next six months. “If we find the same results in patient samples, we would expect that a simple test for docetaxel resistance could be developed and in clinical use within the next five years,” said Dr. Brown. Such a test would mean that those who would not benefit from docetaxel chemotherapy could be spared its side effects, and also reduce costs for healthcare providers.

“We think that the changes we have found may represent common drug resistance mechanisms in breast cancer cells,” said Dr Brown. “We are currently looking at these findings in other cancer types, especially those which are also treated with docetaxel, to see if the results may have a potential in other areas. This is the first time that the genetic pathways involved in the evolution of acquired resistance to docetaxel have been identified in a docetaxel resistant cell line model.”

Mary Rice | alfa
Further information:
http://www.ecco-org.eu

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>